Article
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Clinical colorectal cancer - 1 Jun 2015
Kaczirek Klaus, Ciuleanu Tudor E, Vrbanec Damir, Marton Erika, Messinger Diethelm, Liegl-Atzwanger Bernadette, Wrba Fritz, Knittelfelder Regina, Lindner Elisabeth, Zielinski Christoph C, Streubel Berthold, Brodowicz Thomas
Abstract excerpt
BACKGROUND: This updated analysis of the CECOG/CORE 1.2.002 study investigated the association between clinical outcome and RAS and BRAF mutations in metastatic colorectal cancer (mCRC) patients treated with FOLFOX4 plus cetuximab. PATIENTS AND METHODS: Available DNA samples from CECOG/CORE 1.2.002 study patients with KRAS exon 2 wild type (wt) (at codons 12 and 13) tumors were screened for mutations at other...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.